These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15816556)

  • 1. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.
    Pal A; Khan S; Wang YF; Kamath N; Sarkar AK; Ahmad A; Sheikh S; Ali S; Carbonaro D; Zhang A; Ahmad I
    Anticancer Res; 2005; 25(1A):331-41. PubMed ID: 15816556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
    Lei S; Chien PY; Sheikh S; Zhang A; Ali S; Ahmad I
    Anticancer Drugs; 2004 Sep; 15(8):773-8. PubMed ID: 15494639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation, Pharmacokinetic Profile, and Tissue Distribution Studies of a Liposome-Based Formulation of SN-38 Using an UPLC-MS/MS Method.
    Li K; Wang S
    AAPS PharmSciTech; 2016 Dec; 17(6):1450-1456. PubMed ID: 26831446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies.
    Liu H; Lu H; Liao L; Zhang X; Gong T; Zhang Z
    Drug Deliv; 2015; 22(6):701-9. PubMed ID: 24625262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study.
    Fang YP; Chuang CH; Wu YJ; Lin HC; Lu YC
    Int J Nanomedicine; 2018; 13():2789-2802. PubMed ID: 29785106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination by liquid chromatography with fluorescence detection of total 7-ethyl-10-hydroxy-camptothecin (SN-38) in beagle dog plasma after intravenous administration of liposome-based SN-38 (LE-SN38).
    Guo W; Ahmad A; Khan S; Dahhani F; Wang YF; Ahmad I
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 791(1-2):85-92. PubMed ID: 12798168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
    Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
    Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
    Bissery MC; Vrignaud P; Lavelle F; Chabot GG
    Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38).
    Khan S; Ahmad A; Guo W; Wang YF; Abu-Qare A; Ahmad I
    J Pharm Biomed Anal; 2005 Feb; 37(1):135-42. PubMed ID: 15664753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single protein encapsulated SN38 for tumor-targeting treatment.
    Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
    J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies.
    Zhang H; Wang J; Mao W; Huang J; Wu X; Shen Y; Sui M
    J Control Release; 2013 Mar; 166(2):147-58. PubMed ID: 23266448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Irinotecan pharmacokinetics].
    Chabot GG; Robert J; Lokiec F; Canal P
    Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
    Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
    Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
    Sapra P; Zhao H; Mehlig M; Malaby J; Kraft P; Longley C; Greenberger LM; Horak ID
    Clin Cancer Res; 2008 Mar; 14(6):1888-96. PubMed ID: 18347192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
    Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
    Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors.
    Marier JF; Pheng L; Trinh MM; Burris HA; Jones S; Anderson K; Warner S; Porubek D
    J Pharm Sci; 2011 Oct; 100(10):4536-45. PubMed ID: 21630281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sensitive and rapid liquid chromatography tandem mass spectrometry method for quantitative determination of 7-ethyl-10-hydroxycamptothecin (SN-38) in human plasma containing liposome-based SN-38 (LE-SN38).
    Khan S; Ahmad A; Ahmad I
    Biomed Chromatogr; 2003 Dec; 17(8):493-9. PubMed ID: 14648604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of a novel liposome-based formulation of SN-38.
    Zhang JA; Xuan T; Parmar M; Ma L; Ugwu S; Ali S; Ahmad I
    Int J Pharm; 2004 Feb; 270(1-2):93-107. PubMed ID: 14726126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
    Adkins CE; Nounou MI; Hye T; Mohammad AS; Terrell-Hall T; Mohan NK; Eldon MA; Hoch U; Lockman PR
    BMC Cancer; 2015 Oct; 15():685. PubMed ID: 26463521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
    Ramsay EC; Anantha M; Zastre J; Meijs M; Zonderhuis J; Strutt D; Webb MS; Waterhouse D; Bally MB
    Clin Cancer Res; 2008 Feb; 14(4):1208-17. PubMed ID: 18281556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.